[Clinical pharmacokinetics of fluorazole].
The ftorazole pharmacokinetics was studied in 14 patients after the oral administration of 40 and 80 mg as a single dose. The ftorazole concentrations in the serum specimens sampled within 8 hours were determined by GLC with an electron-capture detector. A pronounced variability was inherent in the individual concentration-time profiles: the mean values of the serum peak concentrations (Cmax) following the 40 and 80 mg dosing were 30-119 and 55-195 ng/ml respectively. Nonetheless, a dose-proportional increasing of the areas under the concentration-time curve (AUC) was observed. The mean values (SD) of the AUC related to the dose, absorption lag-time, time for reaching Cmax, the Cmax/AUC ratio as an index of the absorption rate, the elimination half-life and mean residence time were 6.64 (2.98) (ng.h/ml), 0.31 (0.17) h, 1.17 (0.55) h, 0.26 (0.05) h-1, 2.40 (0.70) h and 3.06 (0.28) h respectively. The data obtained are indicative of the ftorazole pharmacokinetics linearity in humans.
Firsov
A A
AA
Kandenatsii
I B
IB
Glezer
M G
MG
Agapitova
I V
IV
Dombrovskiĭ
V S
VS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000930:Antidiarrheals / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016014:Linear Models; D008875:Middle Aged
D000930:Antidiarrheals; D000959:Antihypertensive Agents
Klinicheskaia farmakokinetika ftorazola.